• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NexGel Inc filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8/5/25 4:05:32 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email
    false 0001468929 0001468929 2025-07-31 2025-07-31 0001468929 NXGL:CommonStockParValue0.001Member 2025-07-31 2025-07-31 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2025-07-31 2025-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 31, 2025

     

    NEXGEL, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41173   26-4042544

    (State or other jurisdiction

    of incorporation)

     
     

    (Commission

    File Number)

     
     

    (IRS Employer

    Identification No.)

     

    2150 Cabot Boulevard West, Suite B

    Langhorne, Pennsylvania

      19067
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (215) 702-8550

     

    (Former name or former address, if changed since last report)

    Not Applicable

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act: None

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
    Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On July 31, 2025, Steven A. Ciardiello was appointed to the board of directors (the “Board”) of NexGel, Inc. (the “Company”) to serve for a term expiring at the Company’s next annual meeting of stockholders or his successor is duly elected and qualified. Mr. Ciardiello was also appointed as a member to the Audit Committee of the Board.

     

    Mr. Ciardiello, 54, is the Chief Accounting Officer for Shutterstock, Inc, a leading global creative platform offering high-quality creative content for transformative brands, digital media and marketing companies, serving since November of 2016. In this role, he oversees Shutterstock’s internal and external accounting and reporting, tax services and Sarbanes-Oxley internal control functions. Prior to joining Shutterstock, Mr. Ciardiello served as Head of Accounting at WeWork Companies, Inc., a leading provider of shared workspace, from November 2015 to November 2016, as Vice President - Finance at AmTrust Financial Services, Inc., a multinational provider of specialty property and casualty insurance products, from September 2014 to November 2015, and served in multiple capacities at Tower Group International, Ltd., a property and casualty insurance provider, from July 2010 to September 2014, advancing to Managing Vice President - Chief Accounting Officer. Mr. Ciardiello also worked in public accounting with Deloitte & Touche LLP and PricewaterhouseCoopers LLP for 15 years. Mr. Ciardiello is a Certified Public Accountant and earned a B.A. in economics from the University of Illinois.

     

    There have been (i) no compensation or other arrangements entered into between the Company and Mr. Ciardiello in connection with his appointment to the Board or the Audit Committee except as set forth below with respect to the grant of the option to purchase shares of the Company’s common stock and (ii) no transactions between the Company and Mr. Ciardiello or his immediate family members requiring disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.

     

    In connection with Mr. Ciardiello’s appointment to the Board, the Board granted Mr. Ciardiello an option to purchase up to 30,000 shares of the Company’s common stock (the “Option Grant”) pursuant to the Company’s 2019 Long-Term Incentive Plan, as amended (the “Plan”), for his services as a member of the Board until the Company’s 2026 Annual Meeting of Stockholders. The exercise price of the Option Grant is $2.25 per share, which was the Fair Market Value (as defined in the Plan) of the Company’s common stock on July 31, 2025. The number of shares underlying the Option Grant vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to Mr. Ciardiello’s continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan.

     

    Item 8.01 Other Events.

     

    On August 5, 2025, the Company issued a press release regarding the appointment of Mr. Ciardiello to the Board.  A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference in its entirety.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit    
    No.   Description
         
    99.1   Press release of NexGel, Inc. issued August 5, 2025.
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 5, 2025    
         
      NEXGEL, INC.
         
      By: /s/ Adam Levy
        Adam Levy
        Chief Executive Officer

     

     

     

    Get the next $NXGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    SEC Filings

    View All

    SEC Form 10-Q filed by NexGel Inc

    10-Q - NEXGEL, INC. (0001468929) (Filer)

    8/12/25 5:01:21 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    8/12/25 4:10:58 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    8/5/25 4:05:32 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on NexGel with a new price target

    Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

    2/25/22 9:17:01 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:14 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:12 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:08 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Ciardiello Steven claimed ownership of 21,739 shares (SEC Form 3)

    3 - NEXGEL, INC. (0001468929) (Issuer)

    8/5/25 4:10:16 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Henry Scott Robert

    4 - NEXGEL, INC. (0001468929) (Issuer)

    6/27/25 8:00:09 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Zeldis Jerome B

    4 - NEXGEL, INC. (0001468929) (Issuer)

    6/27/25 8:00:07 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    View All

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

    LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader

    8/5/25 8:00:00 AM ET
    $NXGL
    $SSTK
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

    LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati

    1/2/25 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

    LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e

    10/4/24 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reports Second Quarter 2025 Financial Results

    Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio

    8/12/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I

    8/6/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

    LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader

    8/5/25 8:00:00 AM ET
    $NXGL
    $SSTK
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $NXGL
    Financials

    Live finance-specific insights

    View All

    NEXGEL Reports Second Quarter 2025 Financial Results

    Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio

    8/12/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I

    8/6/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reports First Quarter 2025 Financial Results

    First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

    5/13/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care